[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ad---alzheimers-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ad---alzheimers-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100642440","temporal-interference-stimulation-treatment-in-patients-with-cognitive-impairment-100642440",false,"NCT07643363","Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","A Randomized, Sham-Controlled Trial of Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment","TIS","Inclusion Criteria:\n\n* meets the criteria for probable AD and MCI due to AD as defined by the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) guidelines;\n* Positive amyloid biomarker (amyloid PET or CSF tTau\u002FAβ 42);\n* Positive tau biomarker (tau-PET or CSF pTau181);\n* AD-related standard treatments (acetyl cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists) taken at a stable dose for at least 12 weeks prior to baseline.\n* meets the criteria for probable bvFTD as defined by the revised diagnostic criteria for the behavioural variant of frontotemporal dementia (2011), or PPA as defined by the Classification of primary progressive aphasia and its variants (2011);\n* Optional genetic confirmation of FTD-related pathogenic mutations (if available).\n* Aged between 45 and 85 years, inclusive; no gender limitation.\n* Right-handed.\n* Education level ≥ 3 years.\n* Mini-Mental State Examination (MMSE) score ≥ 11.\n* Clinical Dementia Rating (CDR) score of 1 or 2.\n* with a reliable caregiver\n* Able to cooperate with cognitive assessments and cognitive training procedures.\n* Full understanding of the study, voluntary participation, and provision of written informed consent approved by the Ethics Committee.\n\nExclusion Criteria:\n\n* Diagnosis of other types of dementia or major neurological disorders (e.g., stroke, epilepsy, Lewy body dementia, vascular dementia, Parkinson's disease dementia, Huntington's disease).\n* Major psychiatric disorders such as severe depression or anxiety.\n* Severe systemic or organ dysfunction (e.g., heart failure III-IV, liver cirrhosis, renal failure).\n* Use of medications that significantly affect cognition (e.g., anticholinergics, sedatives), unless approved by the physician.\n* Presence of metal implants incompatible with MRI or TIS (e.g., pacemakers, deep brain stimulators).\n* Skull defects or cranial abnormalities.\n* Inability to tolerate EEG or head stabilization.\n* Severe visual or hearing impairment preventing task performance.\n* History of alcohol or drug abuse.\n* Participation in another clinical trial within the past 3 months.\n* Current or recent treatment with anti-amyloid monoclonal antibodies (e.g., lecanemab, donanemab).","ALL","45 Years","85 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the efficacy and safety of temporal interference stimulation (TIS), a non-invasive neuromodulation technique, in improving cognitive function in patients with cognitive impairment. TIS uses two high-frequency currents applied transcranially, which intersect within the brain to generate a low-frequency modulation field. This technique selectively modulates deep brain regions while minimizing the stimulation of superficial cortical layers.\n\nParticipants will undergo individualized MRI-based modeling to determine the optimal electrode placement and stimulation parameters. The intervention consists of 10 stimulation sessions over a period of 14 days, using either active TIS or sham stimulation. Cognitive assessments, EEG recordings, and functional MRI scans will be conducted at baseline; 5 days after intervention initiation; at the end of the 10-day intervention; and during follow-up assessments at 4 weeks, 8 weeks, and 12 weeks post-intervention to evaluate both immediate and long-term effects on cognitive performance and neural activity.\n\nThe study aims to determine whether TIS can serve as a feasible and effective neuromodulation strategy for individuals with cognitive impairment.",[28,29,30,31],"Amnestic Mild Cognitive Impairment - aMCI","AD-MCI","AD - Alzheimer's Disease","FTD",[33,34,35],"Temporal Interference Stimulation","Alzheimer's Disease","Frontotemporal Dementia","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-11","ACTUAL",{"date":42,"type":22},"2026-07-01",{"date":44,"type":22},"2029-06",{"name":46,"class":47},"Tianjin Huanhu Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":48},"100637171","phase-1-a-phase-i-study-of-18fflortaucipir-pet-imaging-in-chinese-subjects-safety-pharmacokinetics-biodistribution-radiation-dosimetry-and-preliminary-diagnostic-efficacy-100637171","NCT07580703","A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy","A Non Randomized, Open-Label Phase I Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry, and Preliminary Diagnostic Efficacy of [18F]Flortaucipir Injection PET Imaging in Chinese Subjects","Inclusion Criteria:\n\n* Signed informed consent form (ICF).\n* Male or female aged 50-85 years.\n* Education level sufficient to cooperate with neuropsychological testing and obtain reliable results.\n* Meet the following criteria related to cognitive impairment:\n\n  1. CN: No history of cognitive impairment, Aβ-PET negative, MRI without clinically significant neurodegenerative changes.\n  2. MCI: Meet core criteria for AD-related MCI, Aβ-PET positive, MRI showing neurodegenerative changes.\n  3. AD: Meet core criteria for probable AD dementia, Aβ-PET positive, MRI showing neurodegenerative changes.\n* Fertile individuals: No plan for reproduction, sperm\u002Fegg donation within 6 months after signing ICF and until 6 months after study drug administration; and agreement to use highly effective contraception (including partner).\n\nExclusion Criteria:\n\n* Pregnant (positive pregnancy test at screening or before administration) or breastfeeding women.\n* Major surgery within 1 month prior to screening, or planned surgery during the study period.\n* Known allergy to radioactive radiation, alcohol, \\[18F\\]Flortaucipir injection, or its excipients, or other severe allergic reactions.\n* Cognitive impairment due to causes other than AD.\n* Clinically significant infarction or probable multi-infarct dementia.\n* Current clinically significant psychiatric illness (e.g., major depression, schizophrenia).\n* History of epilepsy or seizures (except febrile seizures in childhood).\n* Inability to tolerate PET\u002FMRI or presence of contraindications to PET\u002FMRI.\n* Other neurodegenerative diseases or dementias other than AD dementia.\n* Any other condition that, in the investigator's opinion, makes the subject unsuitable for the study.",true,"50 Years",{"count":59,"type":22},18,[61],"PHASE1","This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called \\[18F\\]Flortaucipir Injection, which is used during a PET scan. The study will also measure how the agent moves through the body (pharmacokinetics), where it goes (biodistribution), the amount of radiation exposure (radiation dosimetry), and how well it may help detect signs of disease (preliminary diagnostic efficacy).",[30,64],"MCI",[66,67,68,69,70,71,72,64],"tau-PET","[18F]Flortaucipir","Phase I","ELI-101","ELI-101-001","AD","Alzheimer's disease","2026-05-11",{"date":75,"type":40},"2026-05-14",{"date":77,"type":40},"2026-04-23",{"date":79,"type":22},"2027-03-31",{"name":81,"class":82},"Eli Radiopharma","INDUSTRY",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":56,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100619665","neurocare-community-project-a-community-based-prospective-observational-study-for-early-alzheimers-detection-in-hk-100619665","NCT07347574","NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK","NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in Hong Kong","Inclusion Criteria:\n\n* Mentally capable of providing informed consent, with or without an informant present\n* Willing and able to undergo blood draw and complete study related assessments; willing to be contacted for follow-up\n\nExclusion Criteria:\n\n* Lacks capacity to consent even with an informant present\n* Refuses or is unable to provide blood samples or complete essential assessments\n* Currently enrolled in another clinical trial that could interfere with this study\n* Known illness that prevents longitudinal follow up or uncontrolled medical illness such as neurodevelopmental disorder, neurodegenerative disease, epilepsy, central nervous system infection, neuroinflammatory diseases, brain tumor, cerebrovascular diseases, history of major psychiatric illness, history of major head injury with altered consciousness, sexually transmitted disease including HIV and syphilis, visual and auditory disability, history of alcohol dependence, substance use disorder, systemic autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, or malignancy.\n* Active delirium or evidence of reversible\u002Fsecondary causes of cognitive impairment (e.g., vitamin B12 deficiency, hypothyroidism) until treated\u002F stabilized","60 Years","75 Years",{"count":93,"type":22},2500,"OBSERVATIONAL","Population aging is reshaping societal dynamics and presents significant global challenges. By 2050, it is projected that 1.6 billion people worldwide will be over the age of 65. Given that aging is the primary risk factor for many common chronic diseases, reducing the burden of age-related illnesses and promoting healthy aging have become critical public health priorities. Notably, Hong Kong has one of the largest proportions of elderly and the highest life expectancy in the world. Dementia, particularly Alzheimer's disease (AD), is a multifaceted condition influenced by both biological and behavioral factors. There is a paucity of robust, community-based prospective data in ethnic Chinese populations that integrate clinical and cognitive measures with objective biomarkers and neuroimaging, especially at earlier stages such as mild cognitive impairment (MCI) and early AD. This community-based project aims to establish a cohort of elderly in Hong Kong, with longitudinal follow-up for 2-3 years. A key strength of this research is the incorporation of a panel of blood biomarkers, which will provide a less invasive and more affordable screening tool to identify Alzheimer's disease at a much earlier stage in the community. Additionally, through benchmark with MRI and PET imaging gold standard, these biomarkers have the potential to predict the conversion risk 1) from clinically normal to mild cognitive impairment and Alzheimer's disease (AD dementia); 2) from clinically MCI to Alzheimer's disease (MCI-AD dementia) or remain static; and differentiate non-AD dementia from Alzheimer's disease (dementia-AD). Collectively, these data will facilitate monitoring of aging processes and cognitive decline, help to identify candidate modifiable factors associated with resilience, and generate a de-identified, Chinese-specific resource to advance healthy aging in Hong Kong.",[30,97,98,99],"Mild Cognitive Impairment","Normal Cognition","Dementia",[72,101,102,103,104],"PET imaging","MR imaging","Biomarker","Amyloid","NOT_YET_RECRUITING","2026-01-15",{"date":108,"type":40},"2026-01-20",{"date":110,"type":22},"2026-02-01",{"date":112,"type":22},"2030-12-30",{"name":114,"class":47},"Hong Kong University of Science and Technology"]